Amarin reported $-7.74M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
AbbVie USD 186M 752M Sep/2025
Alnylam Pharmaceuticals USD 251.08M 317.36M Sep/2025
Amarin USD -7.74M 6.4M Sep/2025
AstraZeneca USD 2.53B 83M Sep/2025
DBV Technologies USD -33.16M 8.71M Sep/2025
GlaxoSmithKline GBP 2.01B 570M Sep/2025
Halozyme Therapeutics USD 175.22M 10.06M Sep/2025
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novartis USD 3.93B 96M Sep/2025